Ji Yun Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ji Yun Kim has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Adela R. Cardones
Department of Dermatology and
1 shared publicationBenny J. Chen
Department of Medicine, Division of Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, North Carolina, USA
1 shared publicationDaniel R. Saban
Department of Ophthalmology, Duke University Medical Center, Durham, North Carolina, USA
1 shared publication- Diana M. Cardona
Department of Pathology, Duke University Medical Center, Durham, North Carolina
1 shared publication - Hsuan Su
Department of Medicine, Division of Hematologic Malignancies and Cellular Therapy, and
1 shared publication John S. Sundy
Inflammation/Respiratory Section, Gilead Sciences, Foster City, California, USA
1 shared publication
Latest Publications
- Open Access
- 4 October 2018
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 3 (19)
SYK inhibitor entospletinib prevents ocular and skin GVHD in mice
Graft-versus-host disease (GVHD) is a major complication of hematopoietic stem cell transplantation (HCT). The tyrosine kinase SYK contributes to both acute and chronic GVHD development, making it an attractive target for GVHD prevention. Entospletinib (ENTO) is a second-generation highly selective SYK inhibitor with a high safety profile. Potential utility of ENTO as GVHD prophylaxis in patients was examined using a preclinical mouse model of eye and skin GVHD and ENTO-compounded chow. We found that early SYK inhibition improved blood immune cell reconstitution in GVHD mice and prolonged survival, with 60% of mice surviving to day +120 compared with 10% of mice treated with placebo. Compared with mice receiving placebo, mice receiving ENTO had dramatic improvements in clinical eye scores, alopecia scores, and skin scores. Infiltrating SYK + cells expressing B220 or F4/80, resembling SYK + cells found in lichenoid skin lesions of chronic GVHD patients, were abundant in the skin of placebo mice but were rare in ENTO-treated mice. Thus, ENTO given early after HCT safely prevented GVHD.
- 4 October 2018
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 3 (19)
Open AccessSYK inhibitor entospletinib prevents ocular and skin GVHD in mice
Graft-versus-host disease (GVHD) is a major complication of hematopoietic stem cell transplantation (HCT). The tyrosine kinase SYK contributes to both acute and chronic GVHD development, making it an attractive target for GVHD prevention. Entospletinib (ENTO) is a second-generation highly selective SYK inhibitor with a high safety profile. Potential utility of ENTO as GVHD prophylaxis in patients was examined using a preclinical mouse model of eye and skin GVHD and ENTO-compounded chow. We found that early SYK inhibition improved blood immune cell reconstitution in GVHD mice and prolonged survival, with 60% of mice surviving to day +120 compared with 10% of mice treated with placebo. Compared with mice receiving placebo, mice receiving ENTO had dramatic improvements in clinical eye scores, alopecia scores, and skin scores. Infiltrating SYK + cells expressing B220 or F4/80, resembling SYK + cells found in lichenoid skin lesions of chronic GVHD patients, were abundant in the skin of placebo mice but were rare in ENTO-treated mice. Thus, ENTO given early after HCT safely prevented GVHD.